Addressing this question will add more mechanistic insights into how epigenetic-metabolic crosstalk contributes to tumor growth, and more importantly, uncover metabolic vulnerabilities that could be exploited to enhance the therapeutic efficacy of BET inhibition in cancer. The gene discussed is DNER; the disease is cancer.